1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
MicroRNAs Research Initiative in Glioblastoma Stem Cells is a grant from Brain Cancer Canada that funds cutting-edge research into novel therapeutic strategies for glioblastoma, the most aggressive and treatment-resistant brain cancer in adults.
The $85,000 award supports the project "Exploring microRNA as Targets for Glioblastoma Therapy," led by Dr. Leonardo Salmena at the University of Toronto, which focuses on identifying microRNA targets in glioblastoma stem cells that could be exploited for new treatments. Fewer than 5% of glioblastoma patients survive five years post-diagnosis, making this research area a critical priority.
Eligible recipients are researchers affiliated with universities or research institutions focused on glioblastoma.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada - Brain Cancer Canada Patient & Caregiver Resources Patient & Caregiver Resources MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada A cutting-edge research initiative led by Dr. Leonardo Salmena at the University of Toronto.
The project, titled "Exploring microRNA as Targets for Glioblastoma Therapy”, focuses on developing novel therapeutic strategies to address one of the most aggressive and treatment-resistant forms of brain cancer. Glioblastoma (GBM) is the most common and lethal brain malignancy in adults, with fewer than 5% of patients surviving five years after diagnosis.
Current treatments are largely ineffective, in part due to a population of cells known as glioblastoma stem cells (GSCs), which are believed to drive tumour growth and resistance to therapy. Despite their importance, significant gaps remain in the understanding of GSC biology. This work represents an important advancement in the field, offering a promising path toward more effective treatments for this devastating disease.
"I'm really proud of our team's hard work in moving this project forward. We truly believe it could change how we think about and treat GBM. ”, says Dr. Salmena.
“We're very thankful to Brain Cancer Canada and the extraordinary contributions of grass roots fundraisers from across Canada that make this grant possible, including: Run for Jayne, Move to Promote GBM, Ride for Don, Julia Coey Memorial, Farands for the Fight.
” Read the Full Press Release MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada PO Box 30007 RPO Woodbine Heights cure@braincancercanada. ca Charitable Registration Number PO Box 30007 RPO Woodbine Heights cure@braincancercanada. ca Charitable Registration Number
According to the current listing, eligibility includes: Researchers focusing on glioblastoma stem cell research. Confirm the full requirements in the official notice before applying.
The current listing shows $85,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
MicroRNAs Research Initiative in Glioblastoma Stem Cells is funded by Brain Cancer Canada. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ARPA-H's HEARING program (ARPA-H-SOL-26-154) — Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy — held its Proposers' Day on June 8, 2026 and set Solution Summary deadlines for June 29 with Full Proposals due August 14. Single prime awardee, multiple Other Transaction Agreements, three integrated technical areas spanning intracortical recording and stimulation devices, wearable dynamic sound modulators, and AI-based auditory read/write algorithms. The first phase runs 18 months; the full effort runs 4.5 years through first-in-human clinical studies. For neurotech teams that have spent a decade in cochlear-implant or visual-prosthesis space, this is the moment the federal government bet on auditory cortex over the cochlea.
Read articleA Nature poll finds three-quarters of American scientists are considering working abroad. ERC applications from U.S. researchers have tripled. France and the EU pledged €500 million to recruit them. Inside the brain drain reshaping global science — and what it means for grant strategy.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read article